Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

scientific article

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1200/JCO.2012.47.3009
P698PubMed publication ID23980090

P50authorJosep M. LlovetQ37393125
Jordi BruixQ37393143
Valérie BoigeQ41786186
Won Young TakQ43284953
Philippe MathurinQ54835963
Thomas DecaensQ62096202
Jean-Luc RaoulQ88195042
Joong-Won ParkQ90067942
Eveline BoucherQ90445694
P2093author name stringIan Walters
Richard S Finn
Masatoshi Kudo
Laetitia Fartoux
Yoon-Koo Kang
Deng-Yn Lin
Ho-Yeong Lim
Ronnie T Poon
Morris Sherman
David Liu
Eric Assenat
Yee Chao
Charissa Chang
Jean-Frédéric Blanc
Rana Ezzeddine
P433issue28
P407language of work or nameEnglishQ1860
P921main subjecthepatocellular carcinomaQ1148337
patientQ181600
P304page(s)3509-3516
P577publication date2013-08-26
P1433published inJournal of Clinical OncologyQ400292
P1476titleBrivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study
P478volume31

Reverse relations

cites work (P2860)
Q642728712018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Q915996602018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Q895580912019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations
Q53212995A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.
Q33442349A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.
Q48036796A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
Q92855692A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma
Q53826807A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
Q42064611A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma
Q85364824A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma
Q87691280A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma
Q36697575A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer
Q38669565A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study
Q36223538A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib
Q53839706A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma.
Q33419633A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
Q38848537Advanced Hepatocellular Cancer: the Current State of Future Research
Q26851033Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up
Q38697243Advances in Local and Systemic Therapies for Hepatocellular Cancer
Q38210345Advances in managing hepatocellular carcinoma
Q38521011Advances in targeted therapies for hepatocellular carcinoma in the genomic era.
Q58700934Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials
Q47954829An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma
Q28075305Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma
Q39210287Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Q33770680Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Q55544709Anti-proliferative Effect of 15,16-Dihydrotanshinone I Through Cell Cycle Arrest and the Regulation of AMP-activated Protein Kinase/Akt/mTOR and Mitogen-activated Protein Kinase Signaling Pathway in Human Hepatocellular Carcinoma Cells.
Q42371684Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review
Q96348711Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma
Q41962614Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Q49545623Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
Q57762740Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial
Q55129610CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma.
Q89057713Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma
Q64092687Cabozantinib for advanced hepatocellular carcinoma
Q56373211Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Q57456582Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials
Q28076867Challenges of advanced hepatocellular carcinoma
Q50169188Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment.
Q35501246Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges
Q41706847Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives
Q37708002Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age.
Q38639762Chemotherapy for hepatocellular carcinoma: The present and the future
Q47775953Chemotherapy for hepatocellular carcinoma: current status and future perspectives
Q92482087CircRNA-100338 Is Associated With mTOR Signaling Pathway and Poor Prognosis in Hepatocellular Carcinoma
Q33594931Cirrhosis and its complications: evidence based treatment
Q42093061Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma
Q37289933Clinical implications of basic research in hepatocellular carcinoma
Q38350799Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review
Q38743040Clinical trials of antiangiogenic therapy for hepatocellular carcinoma
Q28077738Combination treatment including targeted therapy for advanced hepatocellular carcinoma
Q92126376Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States
Q30245396Comparison of hepatocellular carcinoma in Eastern versus Western populations.
Q40218092Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options
Q89623916Controversies in the management of hepatocellular carcinoma
Q38702281Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
Q38155511Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition
Q64959827Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice.
Q38410816Current management of hepatocellular carcinoma: an Eastern perspective
Q38843057Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma
Q27026036Current systemic treatment of hepatocellular carcinoma: A review of the literature
Q34992813DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors
Q58011404Das hepatozelluläre Karzinom
Q38962057Decoding hepatocellular carcinoma: the promise of microRNAs
Q26752854Development and novel therapeutics in hepatocellular carcinoma: a review
Q38201707Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights.
Q55003380Diminished gallbladder filling, increased fecal bile acids, and promotion of colon epithelial cell proliferation and neoplasia in fibroblast growth factor 15-deficient mice.
Q38184582Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy
Q39062384Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity
Q34467228Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.
Q92895892Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial
Q34458068Drug development for hepatocellular carcinoma: knowing the past helps to understand the future
Q27004410Drug therapy for advanced-stage liver cancer
Q34458029Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study
Q58802297Emerging therapies in advanced hepatocellular carcinoma
Q39366121Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma
Q35739362Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma
Q90136508Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis
Q94541665Evolution of Systemic Therapy for Hepatocellular Carcinoma
Q55440708FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma.
Q57073605Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials
Q41595439Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
Q38923517Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma
Q28073654First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation
Q37631655From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers
Q33414726Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies
Q47576283Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.
Q38184833HCC therapies--lessons learned
Q28078111HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists
Q90095535Hepatocellular Carcinoma-How to Determine Therapeutic Options
Q42053469Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy
Q54977952Hepatocellular Carcinoma: Review of Targeted and Immune Therapies.
Q28079378Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment
Q57756376Hepatocellular carcinoma
Q58020832Hepatocellular carcinoma
Q38207012Hepatocellular carcinoma review: current treatment, and evidence-based medicine
Q38554626Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
Q39307416Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists
Q91784372Hepatocellular carcinoma treatment: hurdles, advances and prospects
Q26828407Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting
Q92104133Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets
Q28084046Hepatocellular carcinoma: Where there is unmet need
Q26741201Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?
Q35112053Hepatocellular carcinoma: clinical frontiers and perspectives
Q33895113Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies
Q38246965Hepatocellular carcinoma: systemic therapies and future perspectives
Q90644106Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials
Q91942647Implications of Immunotherapy in Hepatobiliary Tumors
Q92353495Insights into the success and failure of systemic therapy for hepatocellular carcinoma
Q48226736Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Q61805290Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
Q34786090Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial
Q38176242Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning.
Q35903794Liver cancer: Approaching a personalized care
Q38686790Locoregional and systemic therapy for hepatocellular carcinoma
Q58704728Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?
Q92666152Lysyl oxidase induces epithelial-mesenchymal transition and predicts intrahepatic metastasis of hepatocellular carcinoma
Q38444096MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.
Q27014423MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
Q89057715Management of Hepatocellular Carcinoma in Japan as a World-Leading Model
Q87664325Management of hepatocellular carcinoma
Q48105164Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation
Q35550210MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A
Q34974386Minimally invasive local therapies for liver cancer
Q36968841Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators
Q89861316Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma
Q42317924Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives
Q42169289Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?
Q37631288Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition
Q47121307Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review
Q38151670Molecular targeted therapy for hepatocellular carcinoma: current and future
Q38212573Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future
Q57143856Molecular therapies and precision medicine for hepatocellular carcinoma
Q26766689Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?
Q38233004Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment.
Q35434188Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2.
Q89528234New landscapes and horizons in hepatocellular carcinoma therapy
Q38282800New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions
Q96134073Nonsurgical management of advanced hepatocellular carcinoma: a clinical practice guideline
Q38537138Novel drugs in clinical development for hepatocellular carcinoma
Q37542835Novel implications in the treatment of hepatocellular carcinoma
Q47108754Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions.
Q57821063Overexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma
Q38248240Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review
Q26738860Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection
Q38864682PharmGKB summary: sorafenib pathways
Q92446420Pharmacogenetic-Based Interactions between Nutraceuticals and Angiogenesis Inhibitors
Q64949220Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma.
Q33433311Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.
Q39109076Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance).
Q36204431Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients
Q49168467Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma
Q40106296Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib
Q38660065Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial
Q41761530Predicting responsiveness to sorafenib: can the determination of FGF3/FGF4 amplifications enrich for clinical benefit?
Q41489415Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib.
Q98241469Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis
Q38864396Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment
Q26740217Progress in systemic therapy of advanced hepatocellular carcinoma
Q51743178Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies.
Q41344288Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.
Q30236010Recent advances in hepatocellular carcinoma therapy
Q26863748Recent advances in multidisciplinary management of hepatocellular carcinoma
Q57216547Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study
Q42380812Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma
Q38648119Regorafenib as treatment for patients with advanced hepatocellular cancer
Q38785510Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Q38674803Regorafenib for the treatment of unresectable hepatocellular carcinoma.
Q50069191Regorafenib for treatment of hepatocellular carcinoma.
Q47950809Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment
Q55600804Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications.
Q33944599Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer
Q90436245Review article: systemic treatment of hepatocellular carcinoma
Q28551983Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials
Q47869247Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma
Q34728237Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out.
Q34259112Role of liver stem cells in hepatocarcinogenesis
Q28070762Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
Q38354294Role of the fibroblast growth factor receptor axis in cholangiocarcinoma
Q38789875S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial
Q55266511Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma.
Q38971537Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure
Q38264330Second line systemic therapy options for advanced hepatocellular carcinoma; a systematic review.
Q37688967Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis
Q64058271Second-line treatment options in hepatocellular carcinoma
Q94543854Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors
Q30240170Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.
Q64911371Sorafenib for the treatment of hepatocellular carcinoma.
Q98460342Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
Q87226010Sorafenib use in hepatocellular carcinoma: more questions than answers
Q38544841Sorafenib: 10 years after the first pivotal trial.
Q60922494Study progression of anti-angiogenetic therapy and its combination with other agents for the treatment of advanced hepatocellular carcinoma
Q90288455Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Q38708569Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation.
Q42343451Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future
Q58093758Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
Q49907735Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies
Q33593213Systemic therapy for advanced hepatocellular carcinoma: an update
Q26865844Systemic therapy of hepatocellular carcinoma: current status and future perspectives
Q38824017Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium.
Q39112745Systemic treatment for hepatocellular carcinoma: Still unmet expectations
Q97542924Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies
Q38933836Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?
Q57301434Systemic treatments for hepatocellular carcinoma: challenges and future perspectives
Q39295492TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials
Q57055294Targeted and Immune-based Therapies for Hepatocellular Carcinoma
Q64122405Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
Q37702506Targeted therapy in gastrointestinal malignancies
Q42343453Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma.
Q98946916Targeting angiogenesis for liver cancer: Past, present, and future
Q38923977Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma
Q47965755Targets for immunotherapy of liver cancer.
Q46027563The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015): Evidence and Consensus on HCC Management.
Q64962531The Efficacy and Safety of Apatinib Treatment for Patients with Unresectable or Relapsed Liver Cancer: a retrospective study.
Q58797003The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma
Q50579308The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization.
Q38754534The Promise of Immunotherapy in the Treatment of Hepatocellular Carcinoma
Q57053754The Role of Angiogenesis in Hepatocellular Carcinoma
Q48707409The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development.
Q38635474The biology of Hepatocellular carcinoma: implications for genomic and immune therapies
Q44479261The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib
Q34402325The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014
Q52645823The role of tumor microenvironment in resistance to anti-angiogenic therapy.
Q92618573The up-regulation of P62 levels is associated with resistance of sorafenib in hepatocarcinoma cells
Q38497265Therapeutic targeting of fibroblast growth factor receptors in gastric cancer.
Q56384328Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Q38259343Tivantinib: critical review with a focus on hepatocellular carcinoma.
Q47132493Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma
Q38217737Treating advanced hepatocellular carcinoma: How to get out of first gear
Q40955279Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression
Q38236876Treatment of intermediate-stage hepatocellular carcinoma
Q47832831Treatment options after sorafenib failure in patients with hepatocellular carcinoma.
Q64116366Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report
Q95282127Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference
Q37687269Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib
Q39393740Tumor angiogenesis revisited: Regulators and clinical implications.
Q42292467Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma.
Q52654643Upper gastrointestinal malignancies in 2017: current perspectives and future approaches.
Q26797535Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma
Q92628462Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
Q47818290Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
Q42560671Why does every hepatocellular carcinoma clinical trial using molecular targeted agents fail?
Q86758819[Therapy of hepatocellular carcinoma]
Q39032512mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib
Q36771900pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma

Search more.